臺灣博碩士論文加值系統

在繼續找尋2-苯基-4-■唑■酮及2-苯基-4-■■酮類中具有抗癌開發潛能化合物的過程中，本研究合成了一系列6,7,2',3',4',5'-取代-2-苯基-4-■唑■酮及6,2',3',4',5'-取代-2,3-雙氫-2-苯基-4-■唑■酮類衍生物，並進行對抗人類腫瘤細胞之致毒活性及抑制微管蛋白聚合作用的評估，經由這些生物活性的篩選試驗，建立了初步的結構與活性關係，並發現在細胞致毒活性與抑制微管蛋白聚合活性這兩者之間大都具有關連性。其中，6-雜環-2-苯基-4-■唑■酮類衍生物 (56-60) 具有優越的細胞致毒活性，其半數致效濃度 (EC50) 在微莫耳 (mM) 至微毫莫耳 (nM) 濃度之間。尤以2-(3'-甲氧苯基)-6-(■咯啶基)-4-■唑■酮 (57) 之細胞致毒活性最為優越，同時，化合物57也是強效的微管蛋白聚合抑制劑，其活性幾乎與秋水仙鹼、普多非倫毒及combretastatin A-4等天然抗癌物質相當。6,7,2',3',4',5'-取代-2-苯基-4-■唑■酮及6,2',3',4',5'-取代-2,3-雙氫-2-苯基-4-■唑■酮類衍生物對於卵巢癌 (1A9) 及對於vincristine產生抗藥性之鼻咽表皮樣癌 (KB-VIN) 也具有高度選擇性的細胞致毒活性。
另一方面，將2-苯基-4-■唑■酮及2-苯基-4-■■酮類化合物進行烷基化反應，合成一系列4-烷氧基-2-苯基■唑■及4-烷氧基-2-苯基■■類衍生物，並進行抗血小板活性評估。其中，4-乙氧基-2-苯基■唑■(71)、4-甲氧基-2-苯基■■(92)、4-乙氧基-2-苯基■■(93) 及7-氟-4-甲氧基-2-苯基■■(98) 對花生四烯酸所誘導之血小板凝集具有相當強的抑制作用，其活性約為阿司匹靈的10-13倍。
因此，我們將細胞致毒活性特別優越的化合物57及抗血小板活性特別優越的化合物71提供做進一步的藥理機轉研究。

As part of our continuing search for potential anticancer candidates of 2-phenyl-4-quinazolinones and 2-phenyl-4-quinolones, two series of 6,7,2',3',4',5'-substituted 2-phenyl-4-quinazolinones and 6,2',3',4',5'-substituted 2,3-dihydro-2-phenyl-4-quinazolinones have been synthesized and evaluated for cytotoxicity and inhibition of tubulin polymerization. Through these biological screening, a preliminary structure-activity relationship has been established. On the whole, a good correlation was found between the two activities. Among them, 6-N,N-dimethylamino and 6-heterocyclic 2-phenyl-4-quinazolinones (56-60) showed potent cytotoxicity against a panel of human tumor cell lines with EC50 values in the low micromolar to nanomolar concentration ranges. 2-(3'-Methoxyphenyl)-6-(pyrrolidinyl)-4-quinazolinone (57) was especially the most potent. Moreover, compound 57 was also a potent inhibitor of tubulin polymerization with activity comparable to that of the antimitotic natural products such as colchicine, podophyllotoxin, and combretastatin A-4. Substituted 2-phenyl-4-quinazolinones and 2,3-dihydro-2-phenyl-4-quinazolinones also displayed highly selective cytotoxicity against the ovarian cancer (1A9) and vincristine-resistant epidermoid carcinoma of the nasopharynx (KB-VIN).
On the other hand, a series of 4-alkoxy-2-phenylquinazolines and 4-alkoxy-2-phenylquinolines were synthesized respectively via alkylation of 2-phenyl-4-quinazolinones and 2-phenyl-4-quinolones, and their antiplatelet activities were evaluated. Among them, 4-ethoxy-2-phenylquinazoline (71), 4-methoxy-2-phenylquinoline (92), 4-ethoxy-2-phenylquinoline (93) and 7-fluoro-4-methoxy-2-phenylquinoline (98) showed very potent inhibitory effects on the platelet aggregation induced by arachidonic acid. Their activities were about ten to thirteen times more potent than aspirin.
Compound 57 and 71, which exhibited strong cytotoxicity and antiplatelet activity respectively, were thus selected for further investigation of pharmaceutical mechanism.

封面
謝辭
目錄
中文摘要
英文摘要
第一章 緒論
第一節 Quinazolinone類緣化合物之研究概況
第二節 抗癌藥物之概述
第三節 抗血小板藥物之概述
第四節 研究動機與目的
第二章 結果與討論
第一節 化學合成
I. 原料製備
I-1. 2-Amino-5-fluorobenzamide (3) 之合成
I-2. 2-Amino-4,5-substituted benzamides (10, 11, 16) 之合成
I-3. 2-Amino-5-alkylaminobenzamides (25-29) 之合成
II. 標的化合物之合成
II-1. 6,7,2',3',4',5'-Substituted 2-phenyl-4-quinazolinones (41-60)之合成
II-2. 6,2',3',4',5'-Substituted 2,3-dihydro-2-phenyl-4- quinazolinones (61-69) 之合成
II-3. 4-Alkoxy-2-phenylquinazolines (70-79) 及N-alkyl-2-phenylquinazolinones ( 80-86) 之合成
II-4. 4-Alkoxy-2-phenylquinolines (92-99) 及N-alkyl-2-phenylquinolones (100- 104)之合成
第二節 細胞致毒活性
第三節 抑制微管蛋白聚合活性
第四節 抗血小板活性
第三章 結論
第四章 實驗部分
第一節 試藥、溶媒與材料
第二節 重要儀器
第三節　化學合成方法
第四節 藥理試驗方法
參考文獻
已投稿論文
專利申請
圖次

1. Brown, D. J. in: Katritzky and Rees Comprehensive Heterocyclic Chemistry, Vol. 3, Boulton, A. J.; McKillop. A. (eds.), Pergamon Press, Oxford, 1985, pp. 148-149 and references cited therein.
2. Openshaw, H. T. in: The Alkaloids, Vol. 3, R. H. F. Manske (eds.), Academic Press, New York, 1953, pp. 101.
3. Couture, A.; Cornet, H.; Grandclaudon, P. An expeditious synthesis of 2-aryl- and 2-alkylquinazolin-4(3H)-ones. Synthesis 1991, 1009-1010.
4. Bogentoft, C.; Kronberg, L.; Danielsson, B. Studies on the medicinal chemistry of oxoquinazolines. IV. N- and O-alkylation of some 2-substituted 3,4-dihydro-4-oxoquinazolines. Acta Pharm. Suec. 1969, 6 (4), 489-500.
5. Hori, M.; Iemura, R.; Hara, H.; Ozaki, A.; Sukamoto, T.; Ohtaka, H. Novel 4-substituted 2-piperazinylquinazolines as potent anticonvulsive and antihypoxic agents. Chem. Pharm. Bull. 1990, 38 (5), 1286-1291.
6. Yale, H. J.; Kalkstein, M. Substituted 2,3-dihydro-4(1H)-quinazolinones. A new class of inhibitors of cell multiplication. J. Med. Chem. 1967, 10, 334-336.
7. Neil, G. L.; Li, L. H.; Buskirk, H. H.; Moxlcy, T. E. Antitumor effects of the antispermatogenic agent, 2,3-dihydro-2-(1-naphthyl)-4(1H)-quinazolinones. Cancer Chemother. 1972, 56, 163-173.
8. Hamel, E.; Lin, C. M.; Plowman, J.; Wang, H. K.; Lee, K. H.; Paull, K. D. Antitumor 2,3-dihydro-2-(aryl)-4(1H)-quinazolinone deriva-tives. Interactions with tubulin. Biochem. Pharmacol. 1996, 51, 53-59.
9. Jiang, J. B.; Hesson, D. P.; Dusak, B. A.; Dexter, D. L.; Kang, G. J.; Hamel, E. Synthesis and biological evaluation of 2-styrylquinazolin-4(3H)-ones, a new class of antimitotic anticancer agents which inhibit tubulin polymerization. J. Med. Chem. 1990, 33, 1721-1728.
10. Lin, C. M.; Kang, G. J.; Roach, M. C.; Jiang, J. B.; Hesson, D. P.; Luduena, R. F.; Hamel, E. Investigation of the mechanism of the interaction of tubulin with derivatives of 2-styrylquinazolin-4(3H)-one. Mol. Pharmacol. 1991, 40, 827-832.
11. Takeuchi, H.; Hagiwara, S.; Eguchi, S. A new efficient synthesis of imidazolinones and quinazolinone by intramolecular aza-Wittig reaction. Tetrahedron 1989, 45 (20), 6375-6386.
12. Reddy, V. P.; Prasunamba, P. L.; Ratnam, C. V. Synthesis of quinazolin-4-ones & benzimidazoles: fusion of 2-aminobenzamide & 1,2-diaminobenzene with organic acids. Indian J. Chem., Sect. B. 1983, 22 B (9), 917-918.
13. Imai, Y.; Sato, S.; Takasawa, R.; Ueda, M. Facile syntheses of 2H-1,2,4-benzothiadiazine 1,1-dioxides and 4-oxo-3,4-dihydroquinazo-lines from 2-aminobenzenesulfonamide or 2-aminobenzamide and aldehydes in the presence of sodium hydrogen sulfite. Syn. Commun. 1981, 35-36.
14. 韓銳主編，腫瘤化學預防及藥物治療，北京醫科大學暨中國協和醫科大學聯合出版社，1991。
15. Silverman, R. B. in: The Organic Chemistry of Drug Design and Drug Action, Academic Press, Inc., San Diego, 1992, pp. 220-275.
16. Collins, A. R.; Squires, S.; Johnson, R. T. Inhibitors of repair DNA synthesis. Nucleic Acids Res. 1982, 10 (4), 1203-1310.
17. Cadman, E.; Heimer, R.; Davis, L. Enhanced 5-fluorouracil nucleotide formation after methotrexate administration: explanation for drug synergism. Science, 1979, 205 (4411), 1135-1137.
18. Greenberger, L. M.; Williams, S. S.; Horwitz, S. B. Biosynthesis of heterogeneous forms of multidrug resistance-associated glycoproteins. J. Biol. Chem., 1987, 262 (28), 13685-13689.
19. Riordan, J. R.; Deuchars, K.; Kartner, N.; Alon, N.; Trent, J.; Ling, V. Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature, 1985, 316 (6031), 817-819.
20. Marchand, D. H.; Remmel, R. P.; Abdel-Monem, M. M. Biliary excretion of a glutathione conjugate of busulfan and 1,4-diiodobutane in the rat. Drug Metab. Dispos., 1988, 16 (1), 85-92.
21. Liu, L. F. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem., 1989, 58, 351-375.
22. Halligan, B. D.; Edwards, K. A.; Liu, L. F. Purification and characterization of a type II DNA topoisomerase from bovine calf thymus. J. Biol. Chem., 1985, 260 (4), 2475-2482.
23. Champoux, J. J. DNA is linked to the rat liver DNA nicking-closing enzyme by a phosphodiester bond to tyrosine. J. Biol. Chem., 1981, 256 (10), 4805-4809.
24. Rowe, T. C.; Chen, G. L.; Hsiang, Y. H.; Liu, L. F. DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II. Cancer Research. Cancer Res., 1986, 46 (4 Pt 2), 2021-2026.
25. Dervan, P. B. Design of sequence-specific DNA-binding molecules. Science, 1986, 232 (4749), 464-471.
26. Hurley, L. H. DNA and associated targets for drug design. J. Med. Chem., 1989, 32 (9), 2027-2033.
27. Krugh, T. R.; Reinhardt, C. G. Evidence for sequence preferences in the intercalative binding of ethidium bromide to dinucleoside monophosphates. J. Mol. Biol., 1975, 97 (2), 133-162.
28. Hsiang, Y. H.; Liu, L. F.; Wall, M. E.; Wani, M. C.; Nicholas, A. W.; Manikumar, G.; Kirschenbaum, S.; Silber, R.; Potmesil, M. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res., 1989, 49 (16), 4385-4389.
29. Nelson, E. M.; Tewey, K. M.; Liu, L. F. Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4'-(9-acridinylamino)-methanesulfon-m-anisidide. Proc. Natl. Acad. Sci. U.S.A., 1984, 81 (5), 1361-1365.
30. Zhang, H.; D'Arpa, P.; Liu, L. F. A model for tumor cell killing by topoisomerase poisons. Cancer Cells, 1990, 2 (1), 23-27.
31. Bodley, A.; Liu, L. F.; Israel, M.; Seshadri, R.; Koseki, Y.; Giuliani, F. C.; Kirschenbaum, S.; Silber, R.; Potmesil, M. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA. Cancer Res., 1989, 49 (21), 5969-5978.
32. D'Arpa, P.; Liu, L. F. Topoisomerase-targeting antitumor drugs. Biochim. Biophys. Acta., 1989, 989 (2), 163-177.
33. Cain, B. F.; Atwell, G. J.; Seelye, R. N. Potential antitumour agents. 11. 9-Anilinoacridines. J. Med. Chem., 1971, 14 (4), 311-315.
34. Atwell, G. J.; Cain, B. F.; Seelye, R. N. Potential antitumor agents. 12. 9-Anilinoacridines. J. Med. Chem., 1972, 15 (6), 611-615.
35. Denny, W. A.; Cain, B. F.; Atwell, G. J.; Hansch, C.; Panthananickal, A.; Leo, A. Potential antitumor agents. 36. Quantitative relationships between experimental antitumor activity, toxicity, and structure for the general class of 9-anilinoacridine antitumor agents. J. Med. Chem., 1982, 25 (3), 276-315.
36. Zittoun, R.; Bury, J.; Stryckmans, P.; Lowenberg, B.; Peetermans, M.; Rozendaal, K. Y.; Haanen, C.; Kerkhofs, M.; Jehn, U.; Willemze, R.; Amsacrine with high-dose cytarabine in acute leukemia. Cancer Treat. Rep., 1985, 69 (12), 1447-1448.
37. Cain, B. F.; Atwell, G. J.; Denny, W. A. Potential antitumor agents. 16. 4'-(Acridin-9-ylamino)methanesulfonanilides. J. Med. Chem., 1975, 18 (11), 1110-1117.
38. Braithwaite, A. W.; Baguley, B. C. Existence of an extended series of antitumor compounds which bind to deoxyribonucleic acid by nonintercalative means. Biochemistry, 1980, 19 (6), 1101-1106.
39. Sakore, T. D.; Reddv, B. S.; Sobell, H. M. Visualization of drug-nucleic acid interactions at atomic resolution. IV. Structure of an aminoacridine-dinucleoside monophosphate crystalline complex, 9-aminoacridine-5-iodocytidylyl(3'-5')guanosine. J. Mol. Biol., 1979, 135 (4), 763-785.
40. Denny, W. A.; Baguley, B. C.; Cain, B. F.; Waring, M. J. in: Molecular Aspects of Anticancer Drug Action, Neidle, S.; Waring, M. J. (eds.), 1983, pp. 1.
41. Denny, W. A.; Wakelin, L. P. G. Kinetic and equilibrium studies of the interaction of amsacrine and anilino ring-substituted analogues with DNA. Cancer Res., 1986, 46 (4 Pt 1), 1717-1721.
42. Baguley, B. C.; Denny, W. A.; Atwell, G. J.; Finlay, G. J.; Rewcastle, G. W.; Twigden, S. J.; Wilson, W. R. Synthesis, antitumor activity, and DNA binding properties of a new derivative of amsacrine, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino)phenylamino]-4-acridinecarboxamide. Cancer Res., 1984, 44 (8), 3245-3251.
43. Rowinsky, E. K.; Donehower, R. C. The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmacol. Ther. 1992, 52, 35-84.
44. Verweij, J.; Clavel, M.; Chevalier, B. Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. Ann. Oncol. 1994, 5, 495-505.
45. Hastie, S. B. Interactions of colchicine with tubulin. Pharmacol. Ther. 1991, 51, 377-401.
46. Brossi, A.; Yeh, H. J.; Chrzanowska, M.; Wolff, J.; Hamel, E.; Lin, C. M.; Quinn, F.; Suffness, M.; Silverton, J. Colchicine and its analogues: recent findings. Med. Res. Rev. 1988, 8, 77-94.
47. Xia, Y.; Yang, Z. Y.; Xia, P.; Bastow, K. F.; Tachibana, Y.; Kuo, S. C.; Hamel, E.; Hackl, T.; Lee, K. H. Synthesis and biological evaluation of 6,7,2',3',4'-substituted-1,2,3,4-tetrahydro-2-phenyl-4-quinolones as a new class of antimitotic agents. J. Med. Chem. 1998, 41 (7), 1155-1162.
48. Kuo, S. C.; Lee, H. Z.; Juang, J. P.; Lin, Y. T.; Wu, T. S.; Chang, J. J.; Ledniced, D.; Paull, K. D.; Lin, C. M.; Hamel, E.; Lee, K. H. Synthesis and cytotoxicity of 1,6,7,8 and 4'-substituted 2-phenyl-4-quinolones and related compounds: identification as antimitotic agents interacting with tubulin. J. Med. Chem. 1993, 36, 1146-1156.
49. Li, L.; Eang, H. K.; Kuo, S. C.; Lednicer, D.; Lin, C. M.; Hamel, E.; Lee, K. H. 2',3',4',5',5,6,7-Substituted 2-phenyl-4-quinolones and related compounds: their synthesis, cytotoxicity, and inhibition of tubulin polymerization. J. Med. Chem. 1994, 37 (8), 1126-1135.
50. Li, L.; Wang, H. K.; Kuo, S. C.; Wu, T. S.; Mauger, A.; Lin, C. M.; Hamel, E.; Lee, K. H. Synthesis and biological evaluation of 3',6',7-substituted 2-phenyl-4-quinolones as antimitotic antitumor agents. J. Med. Chem. 1994, 37 (20), 3400-3407.
51. Chen, K.; Kuo, S. C.; Hsieh, M.C.; Mauger, A.; Lin, C. M.; Hamel, E.; Lee, K. H. 2',3',4',5,6,7-Substituted 2-phenyl-1,8-naphthyridin-4-ones: their synthesis, cytotoxicity, and inhibition of tubulin polymerization. J. Med. Chem. 1996, 40 (14), 2266-2275.
52. Chen, K.; Kuo, S. C.; Hsieh, M.C.; Mauger, A.; Lin, C. M.; Hamel, E.; Lee, K. H. Synthesis and biological evaluation of substituted 2-aryl-1,8-naphthyridin-4(1H)-ones as antimitotic antitumor agents that inhibit tubulin polymerization. J. Med. Chem. 1997, 40 (19), 3049-3056.
53. Huang, L. J.; Hsieh, M. C.; Teng, C. M.; Lee, K. H.; Kuo, S. C. Synthesis and antiplatelet activity of phenyl quinolones. Bioorg. Med. Chem. 1998, 6, 1657-1662.
54. Hsieh, M. C.; Huang, L. J.; Lee, K. H.; Wu, T. S.; Chen, S. C.; Teng, C. M.; Kuo, S. C. Synthesis and antiplatelet activity of 3,5,6,7,8,2',3' and 4'-monosubstituted 2-phenyl-4-quinolones. Chin. Pharm. J. 1998, 50, 67-80.
55. Hsieh, M. C.; Huang, L. J.; Wu, T. S.; Lee, K. H.; Teng, C. M.; Kuo, S. C. Synthesis and antiplatelet activity of 3,5,6,7,8,2',3' and 4'-disubstituted 2-phenyl-4-quinolones. Chin. Pharm. J. 1998, 50, 277-288.
56. Lee, K. H.; Lin, Y. M.; Wu, T. S.; Zhang, D. C.; Yamagishi, T.; Hayashi, T.; Hall, I. H.; Chang, J. J.; Wu, R. Y.; Yang, T. H. The cytotoxic principles of Prunella vulgaris, Psychotria serpens, and Hyptis captitata: Ursolic acid and related derivatives. Planta Med. 1988, 54, 308-312.
57. Boyd, M. R. Status of the NCI preclinical antitumor drug discovery screen. In Cancer: Principles and Practice of Oncology Updates; De Vita, V. T., Hellman, S., Rosenberg, S. A., Eds; J. B. Lippincoft: Philadelphia, 1989; pp 1-12.
58. Monks, A.; Scudiero, D.; Skehan, P.; Shoemaker, R.; Paull, K.; Vistica, D.; Hose, C.; Langley, J.; Cronise, P.; Vaigro-Woiff, A.; Gray-Goodrich, M.; Campbell, H.; Mayo, J.; Boyd, M. Feasibility of a high-flux anticancer drug screen utilizing a derived panel of human tumor cell lines in culture. J. Natl. Cancer Inst. 1991, 83, 757-766.
59. Hamel, E.; Lin, C. M. Separation of active tubulin and microtubule-associated proteins by ultracentrifugation and isolation of a component causing the formation of microtubule bundles. Biochemistry 1984, 23, 4173-4184.
60. D'Amato, R. J.; Lin, C. M.; Flynn, E.; Folkman, J.; Hamel, E. 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc. Natl. Acad. Sci. U. S. A. 1994, 91, 3964-3968.
61. O'Brien, J. R. Platelet Aggregation II. Some results from a new method of study. J. Clin. Pathol. 1962, 15, 452-455.
62. Teng, C. M.; Chen, W. Y.; Ko, W. C.; Ouyang, C. Antiplatelet effect of butylidenephthalide. Biochem. Biophys. Acta. 1987, 924, 375-382.